No association between omalizumab use and risk of cancer: a nationwide registry‐based cohort study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

No association between omalizumab use and risk of cancer: a nationwide registry‐based cohort study

Published:2022-01-23 Issue: Volume: Page:
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Ali Zarqa¹^ORCID,Egeberg Alexander¹^ORCID,Thyssen Jacob P.¹,Sørensen Jennifer Astrup¹,Vestergaard Christian²^ORCID,Thomsen Simon Francis¹³^ORCID

Affiliation:

1. Department of Dermato‐Venereology and Wound Healing Centre Copenhagen University Hospital Bispebjerg Denmark

2. Department of Dermatology and Venereology Aarhus University Hospital Aarhus Denmark

3. Department of Biomedical Sciences University of Copenhagen Copenhagen Denmark

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.20941

Reference5 articles.

1. Omalizumab: A Review of its Use in Patients with Severe Persistent Allergic Asthma

2. Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria

3. Potential cancer risk with omalizumab? A disproportionality analysis of the WHO's VigiBase pharmacovigilance database

4. The Danish National Patient Registry: a review of content, data quality, and research potential

5. The Danish Civil Registration System as a tool in epidemiology

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Burden of Nonsteroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease: Interplay Between Quality of Life and Economic Implications;The Journal of Allergy and Clinical Immunology: In Practice;2024-07

2. Urticaria and the risk of cancer: a Danish population-based cohort study;British Journal of Dermatology;2024-06-27

3. Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review;Dermatology and Therapy;2024-05-19

4. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database;BioDrugs;2024-03-15

5. Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events;Pharmaceuticals;2023-11-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3